Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors.

Corey C FosterGini F FlemingTheodore G KarrisonChih-Yi LiaoAmi V DesaiJohn W MoroneyMark J RatainRita NandaBlase N PoliteOlwen M HahnPeter H O'DonnellEverett E VokesHedy L KindlerRobyn HseuLinda A JanischJulia DaiMark D HoffmanRalph R WeichselbaumSean P PitrodaSteven J ChmuraJason John Luke

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

SBRT to ≤4 sites with nivolumab+urelumab or nivolumab+cabiralizumab for treating advanced solid tumors is feasible with acceptable toxicity and modest antitumor activity.See related commentary by Rodriguez-Ruiz et al., p. 5443.

Keyphrases

radiation therapy
early stage
radiation induced
locally advanced
drug induced